NVIDIA Director Sells Over $235M in Shares, Highlighting Recent Insider Trades

An NVIDIA Corp. director sold shares valued at approximately $235.6 million in early September, marking the most significant insider transaction reported Wednesday. The sale was part of a broader wave of activity that included substantial stock sales by insiders at Dell Technologies and notable purchases at several smaller companies.

Major Insider Sales

According to regulatory filings, NVIDIA director Mark A. Stevens sold common stock totaling approximately $235.6 million across multiple transactions on September 3 and September 4. The sales were executed at prices ranging from $227.69 to $234.00 per share, as the stock traded near its 52-week high.

Other significant sales reported included:

• Dell Technologies Inc. (DELL): Director Egon Durban and affiliated entity Silver Lake Partners IV, L.P. sold Class C common stock worth a combined $48.1 million on September 4. The sale followed a period of strong performance for the stock, which has gained 336% over the past year.
• BELITE BIO, INC (BLTE): The company's CEO and CFO sold a combined total of over $31.8 million in American depositary shares in early September. The CFO's sales were conducted under a pre-arranged Rule 10b5-1 trading plan.
• Workday, Inc. (WDAY): Director David A. Duffield sold approximately $17.9 million worth of Class A common stock on September 4, also through a Rule 10b5-1 plan.

Notable Insider Buys

Ad

On the buy-side, the largest reported acquisition came from Greenwave Technology Solutions, Inc. CEO Danny Meeks, who acquired 2,152,853 shares valued at $8 million on August 27. Filings clarified this was not an open-market purchase but an exchange for the satisfaction of an outstanding note owed to an entity controlled by the CEO.

At Alumis Inc., director Srinivas Akkaraju, through investment funds, purchased 440,140 shares for a total of $4.9 million on September 4. Other open-market purchases included a $567,580 investment by a director at Inhibrx Biosciences, Inc. and a $70,000 purchase by the CEO of Cytosorbents Corporation.

Context for Investors

Insider transactions are closely watched for potential signals about a company's prospects. While open-market purchases can indicate confidence from executives, sales can be motivated by various factors, including personal financial planning, tax obligations, or portfolio diversification.

The use of Rule 10b5-1 trading plans, as seen in several of this week's large sales, is an important detail. These plans allow insiders to schedule stock sales in advance, which can make the transactions a less direct indicator of an insider's immediate sentiment on the company's outlook.